AIM: Novel oral anticoagulants are characterized by a wide therapeutic window, yet the determination of their plasma-drug concentrations may be useful in some clinical conditions. RESULTS: An LC-MS/MS method for the analysis of dabigatran, apixaban and rivaroxaban in human plasma has been successfully developed and validated. The analysis of plasma samples from patients given other concomitant drugs revealed no significant interference. By reanalysis of samples from patients on anticoagulant therapy, we found the percentage difference in results between the concentration of repeat and the original sample to be within the threshold limit of 20% in 60 of 63 specimens. CONCLUSION: The developed LC-MS/MS assay is easily applicable in the clinical management of patients on anticoagulation therapy.

Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma / Baldelli, Sara; Cattaneo, Dario; Pignatelli, Pasquale; Perrone, Valentina; Pastori, Daniele; Radice, Sonia; Violi, Francesco; Clementi, Emilio. - In: BIOANALYSIS. - ISSN 1757-6180. - ELETTRONICO. - (2016). [10.4155/bio.15.261]

Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma

PIGNATELLI, Pasquale;PASTORI, DANIELE;VIOLI, Francesco;
2016

Abstract

AIM: Novel oral anticoagulants are characterized by a wide therapeutic window, yet the determination of their plasma-drug concentrations may be useful in some clinical conditions. RESULTS: An LC-MS/MS method for the analysis of dabigatran, apixaban and rivaroxaban in human plasma has been successfully developed and validated. The analysis of plasma samples from patients given other concomitant drugs revealed no significant interference. By reanalysis of samples from patients on anticoagulant therapy, we found the percentage difference in results between the concentration of repeat and the original sample to be within the threshold limit of 20% in 60 of 63 specimens. CONCLUSION: The developed LC-MS/MS assay is easily applicable in the clinical management of patients on anticoagulation therapy.
2016
LC–MS/MS; anticoagulants; apixaban; bioanalytical method validation; dabigatran; rivaroxaban
01 Pubblicazione su rivista::01a Articolo in rivista
Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma / Baldelli, Sara; Cattaneo, Dario; Pignatelli, Pasquale; Perrone, Valentina; Pastori, Daniele; Radice, Sonia; Violi, Francesco; Clementi, Emilio. - In: BIOANALYSIS. - ISSN 1757-6180. - ELETTRONICO. - (2016). [10.4155/bio.15.261]
File allegati a questo prodotto
File Dimensione Formato  
Baldelli_Validation_2016.pdf

solo utenti autorizzati

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Creative commons
Dimensione 923.37 kB
Formato Adobe PDF
923.37 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/854017
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 34
social impact